Category: 25137-01-3

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.25137-01-3,(R)-Ethyl piperidine-3-carboxylate,as a common compound, the synthetic route is as follows.

A mixture of 4-fluoro-1-naphthonitrile (300 mg), (R)-ethyl nipecotate (551 mg), potassium carbonate (485 mg), and dimethylsulfoxide (3.0 mL) was stirred at 100 C for 3 hours. After cooling to room temperature, the reactant was poured into water, and then extracted with ethyl acetate. The extracts were washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain ethyl (3R)-1-(4-cyano-1-naphthyl)-3-piperidinecarboxylate (451 mg) (Compound 32). [?]D=-56.4 (c=0.475, MeOH).1H-NMR (200 MHz, CDCl3) ?: 1.26 (3H, t, J=7.0 Hz), 1.70-2.03 (3H, m), 2.14-2.20 (1H, m), 2.79-2.95 (2H, m), 3.07 (1H, t, J=10.6 Hz), 3.35-3.41 (1H, m), 3.57-3.62 (1H, m), 4.17 (2H, q, J=7.0 Hz), 7.06 (1H, d, J=8.2 Hz), 7.54-7.70 (2H, m), 7.84 (1H, d, J=8.2 Hz), 8.13-8.23 (2H, m). IR (KBr) 2216, 1730, 1574 cm-1, 25137-01-3

25137-01-3 (R)-Ethyl piperidine-3-carboxylate 185582, apiperidines compound, is more and more widely used in various fields.

Reference：
Patent; Takeda Pharmaceutical Company Limited; EP1553074; (2005); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

25137-01-3, (R)-Ethyl piperidine-3-carboxylate is a piperidines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

The mixture of ethyl (3R)-piperidine-3-carboxylate (200 mg. 1.27 mmole), benzenesulfonyl chloride (162 muL, 1.27 mmol), and triethylamine (266 muL, 1.91 mmole) in acetonitrile (2.0 mL) was stirred at r.t. for 2 hours. The reaction was quenched with water, extracted with ethyl acetate. The extract was washed with 1N HCl solution, water, brine; dried over Na2SO4. After removal of drying agent, the solution was concentrated to give a residue which was used directly in the next step.

25137-01-3, As the paragraph descriping shows that 25137-01-3 is playing an increasingly important role.

Reference：
Patent; Yao, Wenqing; Li, Yanlong; Xu, Meizhong; Zhuo, Jincong; Zhang, Colin; Metcalf, Brian W.; US2005/288317; (2005); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

25137-01-3, (R)-Ethyl piperidine-3-carboxylate is a piperidines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A mixture of 2-(3-(3-methylphenyl)-3-phenyl-2-propen-1-yloxy)ethanol (16 g, 60 mmol) and triethylamine (15.1 g, 149 mmol) in dry toluene (75 ml) kept under a nitrogen atmosphere was cooled to 5 C. and a solution of methanesulphonyl chloride (13.7 g, 119 mmol) in dry toluene (75 ml) was added dropwise keeping the temperature below 10 C. When addition was complete the reaction mixture was stirred for 1.5 h at 5 C. Water was added (100 ml) and the mixture was stirred at room temperature for 0.5 h. The phases were separated and the aqueous phase was extracted with a small portion of toluene. The combined organic extracts was washed with brine, dried over sodium sulphate and filtered. To the filtrate was added ethyl (R)-3-piperidinecarboxylate (10.3 g, 66 mmol) and potassium carbonate (9.9 g, 72 mmol) and the mixture was heated at reflux temperature for 6 days. Another portion of ethyl (R)-3-piperidinecarboxylate (5.3 g) was added and the mixture was heated at reflux temperature for another 24 h. The reaction mixture was poured into ice water (200 ml) and extracted with ethyl acetate (2*200 ml). The combined organic extracts was washed with a sodium citrate buffer solution (2*100 ml, pH 5) and then extracted with a 5% aqueous citric acid solution (4*100 ml). Toluene (120 ml) was added to the combined acidic extracts and sodium hydroxide pellets was added to the mixture until the pH was measured at 8.5. The phases were separated and the organic phase was dried over sodium sulphate. The solvent was evaporated in vacuo to give 9.4 g (39%) of (R)-N-(2-(3-(3-methylphenyl)-3-phenyl-2-propen-1-yloxy)ethyl)-3-piperidinecarboxylic acid ethyl ester as an oil. TLC: rf=0.50 (SiO2; dichloromethane/methanol/acetic acid=20:2:1).

25137-01-3, 25137-01-3 (R)-Ethyl piperidine-3-carboxylate 185582, apiperidines compound, is more and more widely used in various fields.

Reference：
Patent; Novo Nordisk A/S; US5198451; (1993); A;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

25137-01-3, (R)-Ethyl piperidine-3-carboxylate is a piperidines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A mixture of 2-(3-(3-chlorophenyl)-3-phenyl-2-propen-1-yloxy)ethanol (52.2 g, 0.18 mol) and triethylamine (45.7 g, 0.45 mol) in dry toluene (200 ml) kept under a nitrogen atmosphere was cooled to 5 C. and a solution of methanesulphonyl chloride (41.4 g, 0.36 mol) in dry toluene (200 ml) was added dropwise keeping the temperature below 10 C. When addition was complete the reaction mixture was stirred for 1 h at 5 C. Water was added (250 ml) and the mixture was stirred at room temperature for 10 minutes. The phases were separated and the aqueous phase was extracted with a small portion of toluene. The combined organic extracts were washed with brine and dried over sodium sulphate. The mixture was filtered and the filtrate was reduced in vacuo to approximately 500 ml. Ethyl (R)-3-piperidinecarboxylate (56.8 g, 0.36 mol) and potassium carbonate (49.9 g, 0.36 mol) were added and the mixture was heated at reflux temperature for 7 days. The cooled reaction mixture was poured into water (200 ml) and extracted with ethyl acetate (2*200 ml). The combined organic extracts were washed with a sodium citrate buffer solution (pH 5) and then extracted with a 34% aqueous tartaric acid solution (3*100 ml). The combined acidic aqueous extracts were poured into a mixture of ice water (3 1) and ethyl acetate (400 ml). Sodium hydroxide pellets (27.2 g) was added until pH was measured at ca. 4 and the phases were separated. The organic phase was washed with a 5% sodium bicarbonate solution (3*150 ml) and dried over sodium sulphate. The solvent was evaporated in vacuo to give 57.5 g (74%) of (R)-N-(2-(3-(3-chlorophenyl)-3-phenyl-2-propen-1-yloxy)ethyl)-3-piperidinecarboxylic acid ethyl ester as an oil. TLC: rf=0.45 (SiO2; dichloromethane/methanol/acetic acid=20:2:1)., 25137-01-3

As the paragraph descriping shows that 25137-01-3 is playing an increasingly important role.

Reference：
Patent; Novo Nordisk A/S; US5198451; (1993); A;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

25137-01-3, (R)-Ethyl piperidine-3-carboxylate is a piperidines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Referential Example 3 (3S)-3-aminomethyl-1-(tert-butoxycarbonyl)piperidine The title compound was prepared by a method similar to Referential Example 1, using ethyl (3R)-3-piperidinecarboxylate L(+)-tartarate which was synthesiszed following the method of P. Magnus, et al. [J. Org. Chem., Vol. 56, pp. 1166-1170 (1991)].

25137-01-3, As the paragraph descriping shows that 25137-01-3 is playing an increasingly important role.

Reference：
Patent; BANYU PHARMACEUTICAL CO., LTD.; EP1213281; (2002); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.25137-01-3,(R)-Ethyl piperidine-3-carboxylate,as a common compound, the synthetic route is as follows.

25137-01-3, A mixture of 2-(3-(3-methylphenyl)-3-phenyl-2-propen-1-yl-oxy)ethanol (16 g, 60 mmol) and triethylamine (15.1 g, 149 mmol) in dry toluene (75 ml) kept under a nitrogen atmosphere was cooled to 5 C. and a solution of methanesulphonyl chloride (13.7 g, 119 mmol) in dry toluene (75 ml) was added dropwise keeping the temperature below 10 C. When addition was complete the reaction mixture was stirred for 1.5 h at 5 C. Water was added (100 ml) and the mixture was stirred at room temperature for 0.5 h. The phases were separated and the aqueous phase was extracted with a small portion of toluene. The combined organic extracts was washed with brine, dried (Na2SO4) and filtered. To the filtrate was added ethyl (R)-3-piperidinecarboxylate (10.3 g, 66 mmol) and potassium carbonate (9.9 g, 72 mmol) and the mixture was heated at reflux temperature for 6 days. Another portion of ethyl (R)-3-piperidinecarboxylate (5.3 g) was added and the mixture was heated at reflux temperature for another 24 h. The reaction mixture was poured into ice water (200 ml) and extracted with ethyl acetate (2*200 ml). The combined organic extracts was washed with a sodium citrate buffer solution (2*100 ml, pH 5) and then extracted with a 5% aqueous citric acid solution (4*30 100 ml). Toluene (120 ml) was added to the combined acidic extracts and sodium hydroxide pellets was added to the mixture until the pH was measured at 8.5. The phases were separated and the organic phase was dried (Na2SO4). The solvent was evaporated in vacuo to give 9.4 g (39 %) of (R)-N-(2-(3-(3-methylphenyl)-3-phenyl-2-propen-1-yloxy)ethyl)-3-piperidinecarboxylic acid ethyl ester as an oil. TLC: rf=0.50 (SiO2; dichloromethane/methanol/acetic acid=20:2:1).

As the paragraph descriping shows that 25137-01-3 is playing an increasingly important role.

Reference：
Patent; Novo Nordisk A/S; US6174898; (2001); B1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

25137-01-3, (R)-Ethyl piperidine-3-carboxylate is a piperidines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example 10 (R)-1-(4-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-butyn-1-yl)-3-piperidinecarboxylic Acid A solution containing 5-propargyl-10,11-dihydro-5H-dibenzo[b,f]azepine (2.45 g, 10.5 mmol, prepared similarly as described in U.S. Pat. No. 3,354,178 (1967)), (R)-3-piperidinecarboxylic acid ethyl ester (1.7 g, 10.8 mmol), paraformaldehyde (0.65 g) and a trace of cuprous chloride in dioxane (25 ml) was heated at reflux temperature for 5 h and left standing overnight. The mixture was filtered and the solvent evaporated. The remaining oil was purified by column chromatography on silica gel (40 g) using chloroform as eluent, affording 3.5 g (83%) of (R)-1-(4-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-2-butyn-1-yl)-3-piperidinecarboxylic acid ethyl ester. TLC: Rf=0.55 (SiO2:chloroform/ethanol/ammonium hydroxide=20:1:0.1)., 25137-01-3

The synthetic route of 25137-01-3 has been constantly updated, and we look forward to future research findings.

Reference：
Patent; Novo Nordisk A/S; US6569849; (2003); B1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.25137-01-3,(R)-Ethyl piperidine-3-carboxylate,as a common compound, the synthetic route is as follows.

Example 15 (R)-1-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)methyl)-3-piperidinecarboxylic Acid Hydrochloride Sodium cyano borohydride (314 mg, 5 mmol) was dissolved in dry methanol (6 ml) and added dropwise under stirring to a mixture of 10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylmethanal (1.11 g, 5 mmol, prepared similarly as described in Ger. Offen 2,106 165, 1971, CA 75, 129 687), (R)-3-piperidinecarboxylic acid ethyl ester (1.57 g, 10 mmol) and zinc chloride (0.34 g, 2.5 mmol) in dry methanol (15 ml) over 30 minutes at 25 C. The reaction mixture was stirred at room temperature for 3 h and left to stand overnight. The methanol was evaporated in vacuo and benzene (30 ml) and 1.2 N sodium bicarbonate (15 ml) were added. The phases were separated and the organic phase was washed with water (30 ml) and brine (2*30 ml) and dried (sodium sulfate). The solvent was evaporated in vacuo and the oily residue (1.68 g) was purified by column chromatography on silica gel (35 g) using benzene as eluent. This afforded 1.12 g (62%) of (R)-1-((10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)methyl)-3-piperidinecarboxylic acid ethyl ester. TLC: Rf=0.54 (SiO2:chloroform/methanol=30:1).

25137-01-3, As the paragraph descriping shows that 25137-01-3 is playing an increasingly important role.

Reference：
Patent; Novo Nordisk A/S; US6569849; (2003); B1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.25137-01-3,(R)-Ethyl piperidine-3-carboxylate,as a common compound, the synthetic route is as follows.

25137-01-3, The mixture of ethyl (3R)-piperidine-3-carboxylate (200 mg, 1.27 mmol), o-nitro-benzenesulfonyl chloride (280 mg, 1.30 mmol), triethylamine (266 muL, 1.91 mmol) in acetonitrile (2.0 mL) was stirred at r.t. for 2 hours. The reaction was quenched with water, extracted with ethyl acetate. The extract was washed with 1N HCl solution, water, brine and dried over Na2SO4. After filtration, the filtrate was concentrated to yield a residue.

The synthetic route of 25137-01-3 has been constantly updated, and we look forward to future research findings.

Reference：
Patent; Yao, Wenqing; Li, Yanlong; Xu, Meizhong; Zhuo, Jincong; Zhang, Colin; Metcalf, Brian W.; US2005/288317; (2005); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.25137-01-3,(R)-Ethyl piperidine-3-carboxylate,as a common compound, the synthetic route is as follows.

Step B. Ethyl (3R)-1-{[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}piperidine-3-carboxylateA suspension of 2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazole-5-sulfonyl chloride (300 mg, 0.80 mmol) in DCE (5 mL) was slowly added to a solution of ethyl (3R)-piperidine-3-carboxylate (140 mg, 0.88 mmol) and DIPEA (1.4 mL, 8.0 mmol) in DCE (25 mL). The reaction mixture was stirred overnight at ambient temperature and the solvent was concentrated. The product was purified by MPLC on silica gel using 60-90% EtOAc/Heptane to provide the title compound as white solid. Yield: 265 mg (66%); 1H NMR (400 MHz, CDCl3) delta 1.26 (t, J=7.13 Hz, 3H), 1.33 (td, J=12.55, 4.00 Hz, 1H), 1.50-1.57 (m, 3H), 1.59 (s, 9H), 1.62-1.71 (m, 2H), 1.72-1.84 (m, 1H), 1.90-2.02 (m, 1H), 2.22-2.38 (m, 2H), 2.44 (t, J=11.03 Hz, 1H), 2.57-2.69 (m, 1H), 3.28-3.41 (m, 2H), 3.70 (d, J=11.33 Hz, 1H), 3.91 (dd, J=11.43, 3.81 Hz, 1H), 4.01 (dd, J=11.23, 2.83 Hz, 2H), 4.13 (q, J=7.16 Hz, 2H), 4.25 (d, J=7.42 Hz, 2H), 7.43 (d, J=8.59 Hz, 1H), 7.64 (dd, J=8.40, 1.76 Hz, 1H), 8.18 (d, J=1.17 Hz, 1H); MS (ESI) (M+H)+=492.0.

25137-01-3, As the paragraph descriping shows that 25137-01-3 is playing an increasingly important role.

Reference：
Patent; Brown, William; Liu, Ziping; Page, Daniel; Qadoumi, Zena; Srivastava, Sanjay; Tremblay, Maxime; Walpole, Christopher; Wei, Zhong-yong; Yang, Hua; US2011/86853; (2011); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem